Satsuma Pharmaceuticals, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2021-06-30: Study NCT04940390; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2021-03-05: Study NCT05337254; Company role Lead sponsor; Phase Phase 1; Status Completed.
- 2020-09-14: Study NCT04406649; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2019-06-24: Study NCT03901482; Company role Lead sponsor; Phase Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2021-06-30 | NCT04940390 A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine | Lead sponsor | Phase 3 | Completed Results posted | Migraine; Migraine With Aura; Migraine Without Aura | 1,591 | 2022-10-26 |
| 2021-03-05 | NCT05337254 A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects | Lead sponsor | Phase 1 | Completed | Migraine; Migraine With Aura; Migraine Without Aura | 36 | 2021-06-04 |
| 2020-09-14 | NCT04406649 A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine | Lead sponsor | Phase 3 | Completed Results posted | Migraine; Migraine With Aura; Migraine Without Aura | 482 | 2023-01-16 |
| 2019-06-24 | NCT03901482 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine | Lead sponsor | Phase 3 | Completed Results posted | Migraine; Migraine With Aura; Migraine Without Aura | 1,201 | 2020-08-13 |
| 2018-09-11 | NCT03874832 A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects | Lead sponsor | Phase 1 | Completed | Migraine With Aura; Migraine Without Aura; Migraine | 46 | 2018-11-07 |